IGC Pharma, Inc.
IGC
$0.29
$0.000.32%
AMEX
| 06/30/2026 | 03/31/2026 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -19.21% | -3.94% | -53.64% | 20.59% | 11.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -19.21% | -3.94% | -53.64% | 20.59% | 11.86% |
| Cost of Revenue | 24.71% | 48.86% | -57.01% | 59.63% | 41.94% |
| Gross Profit | -68.83% | -64.29% | -50.00% | -5.52% | -9.94% |
| SG&A Expenses | 19.37% | 207.94% | 35.45% | -26.52% | -72.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.54% | 76.08% | 42.27% | -15.48% | -44.19% |
| Operating Income | -46.14% | -97.27% | -64.72% | 19.62% | 49.86% |
| Income Before Tax | -83.61% | -100.50% | -6.06% | 32.76% | 58.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -83.61% | -100.50% | -6.06% | 32.76% | 58.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -83.61% | -100.50% | -6.06% | 32.76% | 58.51% |
| EBIT | -46.14% | -97.27% | -64.72% | 19.62% | 49.86% |
| EBITDA | -54.65% | -119.78% | -72.14% | 20.11% | 52.47% |
| EPS Basic | -51.81% | -63.33% | 11.06% | 40.98% | 66.59% |
| Normalized Basic EPS | -52.50% | -88.89% | 10.64% | 40.59% | 65.16% |
| EPS Diluted | -51.81% | -63.33% | 11.06% | 40.98% | 66.59% |
| Normalized Diluted EPS | -52.50% | -88.89% | 10.64% | 40.59% | 65.16% |
| Average Basic Shares Outstanding | 20.84% | 23.23% | 19.01% | 14.03% | 23.88% |
| Average Diluted Shares Outstanding | 20.84% | 23.23% | 19.01% | 14.03% | 23.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |